Sandoz US News
Sandoz today announced the US launch of diclofenac 3% gel, an authorized generic version of PharmaDerm’s Solaraze® Gel.
Novartis announced today it has filed a Citizen Petition with the US Food and Drug Administration (FDA), urging the Agency to require that a biosimilar share the same INN as the reference product.
Sandoz welcomes California Governor Jerry Brown’s veto of legislation that threatened to restrict patient access to biosimilars – high-quality follow-on versions of existing biologic medicines to treat complex disorders including cancer and autoimmune diseases.
Visit our multimedia gallery to learn about Sandoz.
Use our Product Catalog tool to search our database for information regarding a specific Sandoz product in the US.
Click below for important links.
Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.
Sandoz is a world leader in generic pharmaceuticals, providing access to a wide array of high-quality, affordable medicines. In the US, Sandoz markets more than 200 different generic drugs, including enoxaparin sodium injection, the first generic version of Lovenox®, and Omnitrope®, the groundbreaking follow-on biologic. Our 2,300 US associates are proud to make Sandoz a "healthy decision."
As part of the Novartis group, we believe that superior quality is the key to our long-term success. Our state-of-the-art technologies, decades of experience, and rigorous across-the-board quality standards all contribute to our broad portfolio of premium quality generic medicines.
We use innovation and expertise to go beyond standard generics and develop even the most complex medicines, which add value to patient healthcare – from generic injectables and ophthalmics to biosimilars and respiratory. Driving patient access to cost-effective treatment is how we are shaping the future of healthcare.
Sandoz was the first company to develop and market follow-on versions of highly-complex biopharmaceuticals. Today, we are the undisputed global leader in this segment and have an industry-leading pipeline that will make essential biologics more affordable for all.